Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lucosacituzumab
- Development stage
- Unknown
- Lead developer
- Sichuan Cancer Hospital
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lucosacituzumab is an investigational antibody-drug conjugate (ADC) being developed for the treatment of solid tumors, specifically extensive-stage small cell lung cancer (ES-SCLC). While the specific target and payload are not explicitly detailed in early trial registries, the suffix -sacituzumab suggests it may be a TROP-2 directed ADC, potentially utilizing a topoisomerase I inhibitor payload similar to sacituzumab govitecan. It is currently being evaluated in Phase II clinical trials in China as a maintenance therapy in combination with immune checkpoint inhibitors for patients with ES-SCLC who have not progressed after first-line platinum-based chemotherapy.
- Other names
- lucositamablucosacituzumab
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on lucosacituzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lucosacituzumab.